These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 38425648)
21. CD93 overexpresses in liver hepatocellular carcinoma and represents a potential immunotherapy target. Jiang Q; Kuai J; Jiang Z; Que W; Wang P; Huang W; Ding W; Zhong L Front Immunol; 2023; 14():1158360. PubMed ID: 37483608 [TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of LRPPRC and its association with immune infiltration in liver hepatocellular carcinoma. Zhang Y; Feng B; Liang Y; Tang Q; Zhang S; Zhang Z; Xu L; Yin J Am J Clin Exp Immunol; 2024; 13(3):105-116. PubMed ID: 39022790 [TBL] [Abstract][Full Text] [Related]
23. A prognostic exosome-related long non-coding RNAs risk model related to the immune microenvironment and therapeutic responses for patients with liver hepatocellular carcinoma. Yue Y; Tao J; An D; Shi L Heliyon; 2024 Jan; 10(2):e24462. PubMed ID: 38293480 [TBL] [Abstract][Full Text] [Related]
24. Comprehensive analysis of SLC43A2 on the tumor immune microenvironment and prognosis of liver hepatocellular carcinoma. Liao Y; Weng J; Chen L; Hu N; Yuan X; Wang J; He F; Cai Y; Huang Q; Wang J; Huang L Front Genet; 2022; 13():911378. PubMed ID: 36186480 [No Abstract] [Full Text] [Related]
25. Identification and validation of functional roles for three MYC-associated genes in hepatocellular carcinoma. Li S; Xue P; Diao X; Fan QY; Ye K; Tang XM; Liu J; Huang ZY; Tang QH; Jia CY; Xin R; Lv ZW; Liu JB; Ma YS; Fu D J Adv Res; 2023 Dec; 54():133-146. PubMed ID: 36716957 [TBL] [Abstract][Full Text] [Related]
26. Effect of urokinase-type plasminogen activator combined with clinical stage and Barcelona Clinic Liver Cancer stage on the prognosis of patients with hepatocellular carcinoma. Wu J; Sun M; Li Z; Shen Y; Wu Y; Zhang H; Xu Z; Gao Q J Gastrointest Oncol; 2023 Jun; 14(3):1434-1450. PubMed ID: 37435232 [TBL] [Abstract][Full Text] [Related]
27. Correlation analysis of RDM1 gene with immune infiltration and clinical prognosis of hepatocellular carcinoma. Qiu C; Li Z; Cao W; Cai X; Ye L; Zhang C; Ma Y; Wang X; Yang Y Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34435618 [TBL] [Abstract][Full Text] [Related]
28. Prognostic impact of MICALL1 and associates with immune infiltration in liver hepatocellular carcinoma patients. Yang Y; Zhao W; Du J; Wang Y Cancer Biomark; 2023; 37(3):147-160. PubMed ID: 37248888 [TBL] [Abstract][Full Text] [Related]
29. Constructing and validating of m7G-related genes prognostic signature for hepatocellular carcinoma and immune infiltration: potential biomarkers for predicting the overall survival. Liu P; Dong C; Shi H; Yan Z; Zhang J; Liu J J Gastrointest Oncol; 2022 Dec; 13(6):3169-3182. PubMed ID: 36636051 [TBL] [Abstract][Full Text] [Related]
30. Prognostic and immunological potential of PPM1G in hepatocellular carcinoma. Lin YR; Yang WJ; Yang GW Aging (Albany NY); 2021 May; 13(9):12929-12954. PubMed ID: 33952716 [TBL] [Abstract][Full Text] [Related]
31. System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma. Yan C; Niu Y; Ma L; Tian L; Ma J J Transl Med; 2022 Oct; 20(1):452. PubMed ID: 36195876 [TBL] [Abstract][Full Text] [Related]
32. Comprehensive Analysis of SLC17A9 and Its Prognostic Value in Hepatocellular Carcinoma. Kui XY; Gao Y; Liu XS; Zeng J; Yang JW; Zhou LM; Liu XY; Zhang Y; Zhang YH; Pei ZJ Front Oncol; 2022; 12():809847. PubMed ID: 35957868 [TBL] [Abstract][Full Text] [Related]
33. COMMD2 Upregulation Mediated by an ncRNA Axis Correlates With an Unfavorable Prognosis and Tumor Immune Infiltration in Liver Hepatocellular Carcinoma. Fang W; Gan Y; Zhang L; Xiong J Front Oncol; 2022; 12():853026. PubMed ID: 35574298 [TBL] [Abstract][Full Text] [Related]
34. Integrated bioinformatics analysis reveals the function and prognostic value of OSBPL3 in hepatocellular carcinoma. Su Y; Xue C; Gu X; Sun Y; Zhang R; Li L Heliyon; 2023 Jun; 9(6):e17223. PubMed ID: 37389070 [TBL] [Abstract][Full Text] [Related]
35. A signature based on neutrophil extracellular trap-related genes for the assessment of prognosis, immunoinfiltration, mutation and therapeutic response in hepatocellular carcinoma. Wang L; Wang Q; Li Y; Qi X; Fan X J Gene Med; 2024 Jan; 26(1):e3588. PubMed ID: 37715643 [TBL] [Abstract][Full Text] [Related]
36. Integrated bioinformatics analysis identified MTHFD1L as a potential biomarker and correlated with immune infiltrates in hepatocellular carcinoma. Chen J; Yang J; Xu Q; Wang Z; Wu J; Pan L; Huang K; Wang C Biosci Rep; 2021 Feb; 41(2):. PubMed ID: 33605411 [TBL] [Abstract][Full Text] [Related]
37. KEAP1 overexpression is correlated with poor prognosis and immune infiltration in liver hepatocellular carcinoma. Wei X; Tang Y; Zheng M; Xu Y; Wang Z Front Med (Lausanne); 2024; 11():1391843. PubMed ID: 38938386 [TBL] [Abstract][Full Text] [Related]
38. Ferroptosis regulator SLC7A11 is a prognostic marker and correlated with PD-L1 and immune cell infiltration in liver hepatocellular carcinoma. Liang Y; Su S; Lun Z; Zhong Z; Yu W; He G; Wang Q; Wang J; Huang S Front Mol Biosci; 2022; 9():1012505. PubMed ID: 36267158 [No Abstract] [Full Text] [Related]
39. ASPM Is a Prognostic Biomarker and Correlates With Immune Infiltration in Kidney Renal Clear Cell Carcinoma and Liver Hepatocellular Carcinoma. Deng T; Liu Y; Zhuang J; Tang Y; Huo Q Front Oncol; 2022; 12():632042. PubMed ID: 35515103 [TBL] [Abstract][Full Text] [Related]
40. Type-1 Na Zhou YT; Chen H; Ai M; Li SS; Li BY; Zhao Y; Cai WW; Hou B; Ni LL; Xu F; Qiu LY Life Sci; 2021 Aug; 278():119613. PubMed ID: 34000263 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]